AI Article Synopsis
- - Intravesical chemotherapy is primarily used for urothelial neoplasia, with Bacillus Calmette-Guerin (BCG) and mitomycin C (MMC) being the standard treatments, while gemcitabine is a less common alternative.
- - The article emphasizes the importance of gemcitabine for treating non-muscle invasive bladder cancer, particularly in cases where standard treatments have failed.
- - A rare case of inverted bladder papilloma, which is linked to non-muscle invasive bladder cancer, is presented, highlighting successful treatment with intravesical gemcitabine after unsuccessful BCG therapy and an allergic reaction to MMC.
Article Abstract
Intravesical chemotherapy instillation is a unique method of treatment confined to urothelial neoplasia. Within the last decades, the substances Bacillus Calmette-Guerin (BCG) and mitomycin C (MMC) have evolved as the standard regimens for intravesical therapy. However, there are other chemotherapeutic substances, which are used less frequently, such as gemcitabine. In this article we aim to highlight the clinical relevance of intravesical gemcitabine instillations as treatment of non-muscle invasive bladder cancer.The histological subtypes of bladder tumours are as diverse as the intravesical regimens. Inverted papilloma is a rare entity in the spectrum of urological diseases. There seems to be an association with non-muscle invasive bladder cancer.We report a rare case of an inverted bladder papilloma treated with intravesical gemcitabine instillations after BCG failure and an allergic reaction to MMC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-1312-9032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravesical Gemcitabine for Non-Muscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure: A Prospective Study.
Asian Pac J Cancer Prev
September 2024
Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran..
Unlabelled: Backgroundsː The objective of this study was to assess the efficacy of gemcitabine as a treatment option for patients diagnosed with non-muscle invasive bladder cancer (NMIBC) who had previously experienced failure with Bacillus Calmette-Guerin (BCG) therapy in the last year.
Methods: We prospectively enrolled 28 patients with recurrent NMIBC after previous intravesical treatment in the last year who declined or were unsuitable for cystectomy between 2021 and 2023. Gemcitabine at 2,000 mg/100 mL was instilled weekly for 6 weeks.
A mucoadhesive-to-penetrating nanomotors-in-hydrogel system for urothelium-oriented intravesical drug delivery.
J Nanobiotechnology
September 2024
Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Intravesical therapy (IT) is widely used to tackle various urological diseases. However, its clinical efficacy is decreased by the impermeability of various barriers presented on the bladder luminal surface, including the urinary mucus layer and the densely packed tissue barrier. In this study, we report a mucoadhesive-to-penetrating nanomotors-in-hydrogel system for urothelium-oriented intravesical drug delivery.
View Article and Find Full Text PDFShort-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea.
Investig Clin Urol
September 2024
Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Article Synopsis
- In high-risk non-muscle-invasive bladder cancer (NMIBC), intravesical Bacillus Calmette-Guérin (BCG) is the primary treatment after tumor removal, but intravesical gemcitabine is being considered due to BCG shortages; this study focuses on gemcitabine's effectiveness in the Korean population.
- Researchers analyzed data from 60 patients who received 6 weeks of weekly intravesical gemcitabine after tumor resection, categorizing them into high-risk and very high-risk groups based on established medical criteria.
- Results indicated that the disease-free survival (DFS) rates were similar for both high-risk and very high-risk patients at various follow-up points, suggesting that gemcit
Bilateral nephrolithiasis and upper tract transitional cell carcinoma in horseshoe kidney.
Curr Urol
September 2024
The Smith Institute for Urology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, USA.
Article Synopsis
- Nephroureterectomy is the standard treatment for high-grade upper tract urothelial carcinoma (UTUC), but exceptions may exist based on individual patient factors.
- A case is presented where a patient with horseshoe kidney and significant kidney issues was successfully treated using a minimally invasive, nephron-sparing method instead of the standard approach.
- This highlights that current treatment guidelines for UTUC may not fit every patient scenario and that personalized treatment plans should be considered in specialized medical centers.
[New therapeutic approaches for non-muscle invasive bladder cancer-is organ preservation also possible after BCG (Bacillus Calmette Guérin)?].
Urologie
October 2024
Universitätsklinik und Poliklinik für Urologie, Universitätsmedizin Halle, Halle, Deutschland.
Bacillus Calmette-Guérin (BCG) therapy is the standard of care in the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). In the absence of a response to BCG and persistent high-grade disease, cystectomy is recommended depending on the clinical risk. A variety of targeted therapy approaches, which aim at immune- and gene-based molecular targets, such as PD-(L)1 and FGFR, are currently being investigated in randomized studies for BCG-unresponsive NMIBC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!